PBMC as Biomarkers of Diabetic Cardiomyopathy (MOBI)
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
Type 2 diabetes (T2D), especially when associated with metabolic syndrome (MS) is at high risk to develop heart failure with preserved ejection fraction (HFpEF) or heart failure with mildly reduced ejection fraction (HFmrEF), and the specific impact of T2D+MS in cardiac function impairment is usually known as "diabetic cardiomyopathy" (DC). Cardiac remodelling (ie hypertrophy) and subtle myocardial dysfunction are highly prevalent in T2D+MS but not specific enough to predict further HFpEF or HFmrEF. Also, current biomarkers can identify but do not predict HFpEF or HFmrEF in T2D patients; Furthermore, specific biomarkers are needed. Peripheral blood mononuclear cells (PBMC) obtained from a peripheral blood sample can provide insights from calcic and inflammatory pathways, and may identify more specific molecular signatures shared between T2D+MS and HFpEF.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Inclusion criteria common to the 4 groups:
- Patient coming for a scheduled cardiology or endocrinology visit as part of their follow-up
- Patient coming on an empty stomach for the blood test
- Male or female aged between 40 and 80 inclusive
- Patient without systemic disease and/or without anti-inflammatory treatment
- Patient not objecting to this research
- Patient accepting the conservation of biological samples and the performance of genetic analyzes
Group 1: No-T2D +MS / No-HF (control group)
- Patient without T2D or MS and without heart failure coming to a consultation or day hospital for another reason (e.g. screening for atypical symptom, etc.)
Group 2: No-T2D +MS / HFpEF or HFmrEF
- Patient without T2D or MS
- HFpEF or HFmrEF. diagnosed
Group 3: T2D+MS / no-HF
- Patient diagnosed with T2D+MS
Group 4: T2D +MS / HFpEF or HFmrEF
- Patient diagnosed with T2D and MS
- HFpEF or HFmrEF. diagnosed
Exclusion criteria
Non-inclusion criteria common to the 4 groups:
- History (ATCD) of cardiovascular disease (valvular (more than moderate valve disease), radiation, post-cardiotoxic chemotherapy, amyloidosis, etc.) other than HFpEF or HFmrEF
- Atrial fibrillation or permanent flutter ( paroxysmal AF is not a non-inclusion criterion: the rhythm must be sinus at the time of the ultrasound)
- Systemic disease and/or anti-inflammatory treatment
- ATCD of known coronary artery disease
- Unbalanced hypertension (>160/100 mmHg)
- Pregnant and lactating women on questioning
- Persons deprived of their liberty by a judicial or administrative decision
- Persons subject to psychiatric care
- Patients subject to a legal protection measure (guardianship, curators)
- Subject participating in another interventional research including a period of exclusion still in progress.
- Chronic kidney disease(GFR<30ml/min/1.73m2)
Group 1: No-T2D +MS / No-HF (control group)
- Presence of diabetes (whatever the type) and MS
- Presence of heart failure or other known heart disease
Group 2: No-T2D +MS / HFpEF or HFmrEF
- Presence of diabetes (whatever the type) and MS
- No Heart failure
- Left Ventricular Ejection Fraction (LVEF) on ultrasound ≤ 40%
Group 3: T2D+MS / no-HF
- Without diabetes or other type of diabetes than T2D
- Presence of Heart failure or other known coronary artery disease
Group 4: T2D +MS / HFpEF or HFmrEF
- Absence of diabetes or presence of another type of diabetes than T2D
- Absence of Heart failure
- LVEF on ultrasound ≤ 40%
Trial design
100 participants in 4 patient groups
Trial contacts and locations
Loading...
Central trial contact
Julia CANTERINI; Hélène THIBAULT, PU,PH
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal